Skip to content

Observational Study on the Efficacy and Safety of Ambroxol and Ezetimibe Intervention in Mucopolysaccharidosis

Observational Study on the Efficacy and Safety of Ambroxol and Ezetimibe Intervention in Mucopolysaccharidosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096829
Enrollment
Unknown
Registered
2025-02-07
Start date
2025-02-28
Completion date
Unknown
Last updated
2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucopolysaccharidosis (including types: I, II, IIIa, IIIb, IIIc, IIId, IVa, IVb, VI, VII, IX, etc.)

Interventions

the group treated with bromhexine hydrochloride followed by ezetimibe (Group 1):first consume Ambroxol Hydrochloride Oral Solution and then Ezetimibe tablets orally
The group treated with ezetimibe followed by bromhexine hydrochloride(Group 2):first consume Ezetimibe tablets orally and then Ambroxol Hydrochloride Oral Solution

Sponsors

Children's Hospital,Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with mucopolysaccharidosis diagnosed clinically through enzymatic and/or genetic testing; 2.Age above 5 years old (mainly considering the age indication for ezetimibe); 3.Informed consent.

Exclusion criteria

Exclusion criteria: 1.Transplantation or stem cell therapy; 2.Liver dysfunction (ALT more than twice the normal level), renal insufficiency (serum creatinine increase >=26.5 µmol/L within 48 hours; serum creatinine increase more than 1.5 times the baseline value and above within 7 days; urine output reduction (<0.5 ml·kg^-1·h^-1) lasting more than 6 hours); 3.Hereditary fructose intolerance; 4.Allergy to ezetimibe, ambroxol, etc.; 5.Pregnant and lactating women; 6.The subject or guardian does not consent.

Design outcomes

Primary

MeasureTime frame
Urinary Glycosaminoglycan (GAG) Levels;Enzyme Activity Testing;improvement in hepatosplenomegaly;improvement in motor ability;improvement in growth rate;improvement in joints;improvement in facial appearance;improvement in skeletal deformities;improvement in cardiac issues;Liver and kidney function;blood lipids;muscle enzymes;blood sugar;

Secondary

MeasureTime frame
improvement in respiratory function;improvement in vision;improvement in hearing;improvement in speech;improvement in intelligence;Adverse reaction;

Countries

China

Contacts

Public ContactZou Chaochun

Children's Hospital,Zhejiang University School of Medicine

15067123060@163.com+86 571 86670072

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026